AstraZeneca falls as FDA advisers reject breast cancer drug use
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory…
proactiveinvestors.co.uk

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
No analyst coverage available for this stock.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $1.9T $1.7T–$2.0T | — | $2171.44 | — | ±18% | High7 |
FY2026(current) | $2.8T $2.6T–$3.0T | ▲ +50.7% | $2853.59 | ▲ +31.4% | ±18% | High6 |
FY2027 | $3.2T $2.6T–$3.9T | ▲ +14.5% | $3299.15 | ▲ +15.6% | ±18% | High7 |
Dividend per payment — last 7 periods
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory…

No company information available